Characterization of d-boroAla as a novel broad-spectrum antibacterial agent targeting d-Ala-d-Ala ligase

Chemical Biology and Drug Design

Volumn 78, Issue 5, 2011, Pages 757-763

  Putty, Sandeep ^a   Rai, Aman ^a   Jamindar, Darshan ^a   Pagano, Paul ^b,d   Quinn, Cheryl L ^b,e   Mima, Takehiko ^c,f   Schweizer, Herbert P ^c   Gutheil, William G ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b PharmOptima   (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

^d Micromyx LLC   (United States)

^e QnA Pharma Consulting LLC   (United States)

^f KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Alanine branch; Antibacterial; Broad spectrum; Cell wall; d Ala d Ala ligase

Indexed keywords

AMINO ACID DERIVATIVE; AMPICILLIN; ANTIBIOTIC AGENT; BOROALANINE PINANEDIOL; BOROGLYCINE PINANEDIOL; CYCLOSERINE; DEXTRO ALANINE DEXTRO ALANINE LIGASE; DEXTRO BOROALANINE PINANEDIOL; DEXTRO BOROHOMOALANINE PINANEDIOL; DEXTRO BOROVALINE PINANEDIOL; TETRACYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ACETYLATION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACILLUS SUBTILIS; BURKHOLDERIA PSEUDOMALLEI; CONTROLLED STUDY; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; INHIBITION KINETICS; LIQUID CHROMATOGRAPHY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SALMONELLA ENTERICA; SALMONELLA TYPHI; SALMONELLA TYPHIMURIUM; SHIGELLA SONNEI; STAPHYLOCOCCUS AUREUS; STRUCTURE ACTIVITY RELATION; TANDEM MASS SPECTROMETRY;

ALANINE; ANTI-BACTERIAL AGENTS; BACILLUS SUBTILIS; BORONIC ACIDS; ESCHERICHIA COLI; MICROBIAL SENSITIVITY TESTS; PEPTIDE SYNTHASES; SALMONELLA TYPHIMURIUM; STAPHYLOCOCCUS AUREUS; STRUCTURE-ACTIVITY RELATIONSHIP;

BACILLUS SUBTILIS; BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; NEGIBACTERIA; POSIBACTERIA; SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM; STAPHYLOCOCCUS AUREUS;

EID: 80054113900     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01210.x     Document Type: Article

References (30)

1. Appelbaum P.C. (2007) Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents;30:398-408.
2. Dijkshoorn L., Nemec A., Seifert H. (2007) An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol;5:939-951.
3. Klevens R.M., Morrison M.A., Nadle J., Petit S., Gershman K., Ray S., Harrison L.H. et al. (2007) Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA;298:1763-1771.
4. O'Neill A.J. (2008) New antibacterial agents for treating infections caused by multi-drug resistant Gram-negative bacteria. Expert Opin Investig Drugs;17:297-302.
5. Taubes G. (2008) The bacteria fight back. Science;321:356-361.
6. Fischbach M.A., Walsh C.T. (2009) Antibiotics for emerging pathogens. Science;325:1089-1093.
7. Kluytmans J., Struelens M. (2009) Meticillin resistant Staphylococcus aureus in the hospital. BMJ;338:b364.
8. Barrett C.T., Barrett J.F. (2003) Antibacterials: are the new entries enough to deal with the emerging resistance problems? Curr Opin Biotechnol;14:621-626.
9. Abbanat D., Macielag M., Bush K. (2003) Novel antibacterial agents for the treatment of serious Gram-positive infections. Expert Opin Investig Drugs;12:379-399.
10. Baltz R.H. (2009) Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. Curr Opin Chem Biol;13:144-151.
11. Pechenov A., Stefanova M.E., Nicholas R.A., Peddi S., Gutheil W.G. (2003) Potential transition state analogue inhibitors for the penicillin-binding proteins. Biochemistry;42:579-588.
12. Nicola G., Peddi S., Stefanova M., Nicholas R.A., Gutheil W.G., Davies C. (2005) Crystal structure of Escherichia coli penicillin-binding protein 5 bound to a tripeptide boronic acid inhibitor: a role for Ser-110 in deacylation. Biochemistry;44:8207-8217.
13. Duncan K., Faraci W.S., Matteson D.S., Walsh C.T. (1989) (1-Aminoethyl)boronic acid: a novel inhibitor for Bacillus stearothermophilus alanine racemase and Salmonella typhimuriumd-alanine:d-alanine ligase (ADP-forming). Biochemistry;28:3541-3549.
14. Matteson D.S., Sadhu K.M. (1984) Synthesis of 1-amino-2-phenylethane-1-boronic acid derivatives. Organometallics;3:614-618.
15. Matteson D.S., Jesthi P.K., Sadhu K.M. (1984) Synthesis and properties of pinanediol α-amido boronic esters. Organometallics;3:1284-1288.
16. Kettner C.A., Shenvi A.B. (1984) Inhibition of the serine proteases leukocyte elastase, pancreatic elastase, cathepsin G, and chymotrypsin by peptide boronic acids. J Biol Chem;259:15106-15114.
17. Venkatraman S., Wu W., Prongay A., Girijavallabhan V., George Njoroge F. (2009) Potent inhibitors of HCV-NS3 protease derived from boronic acids. Bioorg Med Chem Lett;19:180-183.
18. Coutts S.J., Adams J., Krolikowski D., Snow R.J. (1994) Two efficient methods for the cleavage of pinanediol boronate esters yielding the free boronic acids. Tetrahedron Lett;35:5109-5112.
19. Sadhu K.M., Matteson D.S. (1985) (Chloromethyl)lithium: efficient generation and capture by boronic esters and a simple preparation of diisopropyl (chloromethyl)boronate. Organometallics;4:1687-1689.
20. Martichonok V., Jones J.B. (1997) Cysteine proteases such as papain are not inhibited by substrate analogue peptidyl boronic acids. Bioorg Med Chem;5:679-684.
21. Clinical and Laboratory Standards Institute (2009) Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. CLSI document M07-A8, Vol 29, No 2. Eighth edition. Wayne, PA: Clinical and Laboratory Standards Institute.
22. Jamindar D., Gutheil W.G. (2010) A liquid chromatography-tandem mass spectrometry assay for Marfey's derivatives of l-Ala, d-Ala, and d-Ala-d-Ala: application to the in vivo confirmation of alanine racemase as the target of cycloserine in Escherichia coli. Anal Biochem;396:1-7.
23. Matteson D.S., Sadhu K.M. (1983) Boronic ester homologation with 99% chiral selectivity and its use in syntheses of the insect pheromones (3S, 4S)-4-methyl-3-heptanol and exo-brevicomin. J Am Chem Soc;105:2077-2078.
24. Bjorkholm B., Sjolund M., Falk P.G., Berg O.G., Engstrand L., Andersson D.I. (2001) Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori. Proc Natl Acad Sci USA;98:14607-14612.
25. Pachon-Ibanez M.E., Fernandez-Cuenca F., Docobo-Perez F., Pachon J., Pascual A. (2006) Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam. J Antimicrob Chemother;58:689-692.
26. Baquero M.R., Nilsson A.I., Turrientes Mdel C., Sandvang D., Galán J.C., Martínez J.L., Frimodt-Møller N., Baquero F., Andersson D.I. (2004) Polymorphic mutation frequencies in Escherichia coli: emergence of weak mutators in clinical isolates. J Bacteriol;186:5538-5542.
27. Hanninen M.L., Hannula M. (2007) Spontaneous mutation frequency and emergence of ciprofloxacin resistance in Campylobacter jejuni and Campylobacter coli. J Antimicrob Chemother;60:1251-1257.
28. Bondi A., Kornblum J., Forte C. (1957) Inhibition of antibacterial activity of cycloserine by alpha-alanine. Proc Soc Exp Biol Med;96:270-272.
29. Zygmunt W.A. (1962) Reversal of d-cycloserine inhibition of bacterial growth by alanine. J Bacteriol;84:154-156.
30. Tytgat I., Colacino E., Tulkens P.M., Poupaert J.H., Prevost M., Van Bambeke F. (2009) DD-ligases as a potential target for antibiotics: past, present and future. Curr Med Chem;16:2566-2580.